Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13,891.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,550,298 shares of the biopharmaceutical company’s stock after acquiring an additional 2,532,070 shares during the period. GAMMA Investing LLC owned approximately 0.20% of Gilead Sciences worth $285,761,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. FMR LLC lifted its stake in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. Wellington Management Group LLP lifted its stake in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after acquiring an additional 1,058,331 shares during the period. Geode Capital Management LLC lifted its stake in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock valued at $2,608,337,000 after acquiring an additional 749,047 shares during the period. Norges Bank acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $1,789,254,000. Finally, Northern Trust Corp lifted its stake in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $110.35 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a market capitalization of $137.27 billion, a price-to-earnings ratio of 298.24, a PEG ratio of 0.71 and a beta of 0.26. The company has a fifty day simple moving average of $105.49 and a 200-day simple moving average of $100.78. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the sale, the chief financial officer now owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company’s stock, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,929 shares of company stock valued at $5,644,780. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GILD. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price for the company. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.